Somewhat Positive Press Coverage Somewhat Unlikely to Impact Athenex (ATNX) Stock Price

News coverage about Athenex (NASDAQ:ATNX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Athenex earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.1870577931096 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Athenex (NASDAQ:ATNX) opened at $15.87 on Tuesday. Athenex has a one year low of $11.21 and a one year high of $20.79.

Athenex (NASDAQ:ATNX) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.30) EPS for the quarter. equities analysts predict that Athenex will post -2.75 EPS for the current year.

Several research firms have recently issued reports on ATNX. JPMorgan Chase & Co. began coverage on Athenex in a research note on Wednesday, October 18th. They set a “neutral” rating and a $22.20 price target for the company. Laidlaw began coverage on Athenex in a research note on Tuesday, September 19th. They set a “buy” rating and a $36.00 price target for the company. Credit Suisse Group began coverage on Athenex in a research note on Monday, September 18th. They set an “outperform” rating and a $25.00 price target for the company. Finally, BidaskClub downgraded Athenex from a “hold” rating to a “sell” rating in a research note on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $27.64.

ILLEGAL ACTIVITY WARNING: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at

About Athenex

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Insider Buying and Selling by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit